glp 1 agonist or antagonist GIPR/GLP-1R dual therapies for diabetes and weight loss—chemistry, physiology, and clinical applications glp-1_analogs [TUSOM | Pharmwiki]

Systematic review design The authors screened various electronic databases to identify clinical trials that investigated the effect of GLP-1 receptor agonists on different types of substance use disorders (alcohol, nicotine, and cocaine use disorders) in adult patients

Brandt, S

Semaglutide has a cumulative exposure of over 22 million patient-years." "We will continue to invest in a variety of disease states including diabetes, chronic kidney disease, obesity, CV disease, liver disease, and Alzheimers disease, as seen in our robust clinical development programs and outcome studies," the statement continued

Davies, V.R

Back Habener, JF (2024) 'Acknowledgements' 2024 Lasker-DeBaley Clinical Medical Research Award

36 Endogenous GLP-1 has a short half-life (1-2 min), with only 10% reaching systemic circulation due to rapid degradation, which has driven the development of degradation-resistant GLP-1RAs